Aspirin (NSC 27223)

For research use only. Not for use in humans.

目录号:S3017 别名: Acetylsalicylic acid, ASA 中文名称:阿司匹林

Aspirin (NSC 27223) Chemical Structure

CAS No. 50-78-2

Aspirin (NSC 27223, Acetylsalicylic acid, ASA)是水杨酸类不可逆的COX1 and COX2抑制剂,常用作止痛药来缓解轻微疼痛,作为解热药减少发热,并作为一种抗炎药物。Aspirin 可诱导自噬并激发线粒体自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1064.29 现货
RMB 790.92 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Aspirin (NSC 27223)发表文献16篇:

产品安全说明书

COX抑制剂选择性比较

生物活性

产品描述 Aspirin (NSC 27223, Acetylsalicylic acid, ASA)是水杨酸类不可逆的COX1 and COX2抑制剂,常用作止痛药来缓解轻微疼痛,作为解热药减少发热,并作为一种抗炎药物。Aspirin 可诱导自噬并激发线粒体自噬。
靶点
COX2 [1] COX1 [1]
体外研究

Aspirin抑制NF-κB的活化,从而防止NF-κB抑制剂,IκB的降解,因此NF-κB保留在细胞质中。在转染的T细胞中,Aspirin也会抑制NF-κB依赖性Igκ增强子和人免疫缺陷病毒(HIV)长末端重复序列(LTR) 的转录。[1] Aspirin和salicylate在一定程度上被它们对IKK-β的特定抑制介导,从而防止涉及炎症反应发病机理的NF-κB基因激活。[2]在大鼠神经元原代培养物和海马脑片中,Aspirin对兴奋性氨基酸谷氨酸引发的神经毒性具有保护作用。[3]人脐静脉内皮细胞(HUVEC)和中性粒细胞[多形核白细胞(PMN)]共培养时,Aspirin引起一种先前未识别的类花生酸跨细胞生物合成。Aspirin引起乙酰化的PGHS-2和5-脂氧合酶相互作用形成一类独特的类花生酸。[4] Aspirin治疗抑制IRS-1在Ser307上的磷酸化和JNK,c-Jun磷酸化,以及IkappaBalpha在肿瘤坏死因子(TNF)-α处理的3T3-L1和Hep G2细胞中的降解。Aspirin治疗抑制Akt磷酸化和rapamycin (但不作用于细胞外调节激酶或PKCzeta)的哺乳动物靶点对TNF-α的响应。在TNF-α预处理的3T3-L1脂肪细胞,Aspirin减少胰岛素诱导的葡萄糖摄取。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
AGS MWXGeY5kfGmxbjDhd5NigQ>? NGHscIQyPSC2bzC2NEB2dW:uL1ygZYZ1\XJ? NIDhTmsyOiCqcoO= NIDJZYhKdmirYnn0bY9vKG:oIFXzZ4hmemmlaHnhJINwdGlvc4TpcZVt[XSnZDDJUE05KHC{b3T1Z5Rqd25iaX6gbJVu[W5iQVfTJINmdGy|IHH0JFE2KHSxIE[wJJVud2xxTDDh[pRmeiBzMjDodpMh[nliRVzJV2E> M2XRV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUWzNVg{Lz5{MEG1N|E5OzxxYU6=
microglia cells MkPYRY51cW6ndYLvbY5ndGGvbXH0c5J6KGG|c3H5 MV:xOUBucW6| MXLBcpRqdmW3cn;pcoZt[W2vYYTvdpkh[WO2aY\peJkhcW5iTGDTMZN1cW23bHH0[YQhemG2IH3pZ5Jw\2yrYTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFCPQT3zeIlufWyjdHXkJHRZSjJicnXs[YF{\SCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMhdWWjc4Xy[YQhPzBibXnud{Bi\nSncjDQUWEh[2ijbHzlcodmNCCLQ{WwQVMvOTMQvF2= MmrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUO4O|QoRjJ{MUWzPFc1RC:jPh?=
HCT116 MlL1SpVv[3Srb36gZZN{[Xl? M2C4XlEhdU1? NI\KXm43KGi{cx?= Mn;ZTY5pcWKrdHnvckBw\iCWTl[tZYxxcGFvaX7keYNm\CCQRj3rZZBx[UJiYXP0bZZifGmxbjDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XRiMTDtUUBi\nSncjC2JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> NXzZdYRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVQ5OzRpPkKyNVU1QDN2PD;hQi=>
SKBR3 NV\OU|R4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2fiSlMxOCC3TR?= NEHROHo1QCCqcoO= MYTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT2JTOyClZXzsd{BifCB|MECgeW0h[W[2ZYKgOFghcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5 MlzTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUS2NVcoRjJ{NEm0OlE4RC:jPh?=
PANC1 MkK4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYDIWYZxOzByIIXN NF3XUGM1QCCqcoO= NYrM[3V[T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQ{GgZ4VtdHNiYYSgN|AxKHWPIHHmeIVzKDR6IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigQ>? M4H0OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEm0OlE4Lz5{MkS5OFYyPzxxYU6=
PC3 MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFnXO3g{ODBidV2= NEOwTIU1QCCqcoO= Mke1S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGM{KGOnbHzzJIF1KDNyMDD1UUBi\nSncjC0PEBpenNiYomgZYxidWG{IHLseYUh[XO|YYm= MnLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUS2NVcoRjJ{NEm0OlE4RC:jPh?=
MDA-MB-231 M{L4TGZ2dmO2aX;uJIF{e2G7 Ml61NVAxKHWP NXzkXI81OzBibXnudy=> M1;6[WlzemW4ZYLzbYJt\SCrbnjpZol1cW:wIH;mJGNQYC1zIHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjcnHjbIlld26rYzDhZ4llNWmwZIXj[YQhWEeHMjDmc5Ju[XSrb36gZZQhOTByIIXNJIlv[3WkYYTl[EBnd3JiM{CgcYlveyCob3zsc5dm\CCkeTDjc41xd3WwZDD3ZZNpd3W2IH3lZZN2emWmIEOwJI1qdnNicH;zeEBiemGlaHnkc45q[yCjY3nkJINp[WyuZX7n[UBjgSC{YXTpc4ludXWwb3Hzd4F6 NXX1dIlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVE{PTlpPkKzOlUyOzV7PD;hQi=>
THP1 NFHycI1HfW6ldHnvckBie3OjeR?= M4DFeVExOCC3TR?= NGX2e5c{OCCvaX7z NYfpeoVkUXK{ZY\ldpNq[mynIHnubIljcXSrb36gc4YhS0:[LUGgbY4hcHWvYX6gWGhROSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIFz[WOqaXTvcolkKGGlaXStbY5lfWOnZDDUXGIzKG[xcn3heIlwdiCjdDCxNFAhfU1iaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3jveZQhdWWjc4Xy[YQhOzBibXnud{Bxd3O2IHHyZYNpcWSxbnnjJIFkcWRiY3jhcIxmdmenIHL5JJJi\GmxaX3teY5w[XO|YYm= MmD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4NUGzOVkoRjJ|NkWxN|U6RC:jPh?=
HCT116 MV7DfZRwfG:6aXPpeJkh[XO|YYm= NWDRNYI2PDhiaILz MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BOXFRiYYPzZZk> NFu4TWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1NFQxOSd-Mk[3OVA1ODF:L3G+
H9c2 M{LHXmNiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl? Ml\4NUB2VQ>? MmLSPEBpenN? MnT0R4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDJUE03KGmwIIP1dIVzdmG2YX70JIF1KDFidV2gdJJmcW6ldXLheIVlKG[xcjC4JIhzeyCob3zsc5dm\CCkeTDINm8zKGGmZHn0bY9vKG[xcjCyJIhzeyCkeTDFUGlUSQ>? NInYfYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W3OVQ4OSd-Mke1O|U1PzF:L3G+
H9c2 NELLXXBE[XKmaX;wdo91\WO2aY\lJIF{e2G7 M2XKd|EhfU1? MlzCPEBpenN? Mnq1R4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDUUmYu[WyyaHGgbY4he3WyZYLuZZRidnRiYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDhiaILzJIZwdGyxd3XkJIJ6KEh{T{KgZYRlcXSrb36g[o9zKDJiaILzJIlvKHC{ZYPlcoNmKG:oIHzlc452emmwZTDifUBG M2LCclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 NHnWVlNE[XKmaX;wdo91\WO2aY\lJIF{e2G7 M1fU[VEhfU1? M1PrNVghcHK| NXzQ[phKS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IHnuJJJifCCKOXOyJINmdGy|IHHzd4V{e2WmIHHzJIFvfGmxeHnkZY51KGGldHn2bZR6KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4hVUSDIHzleoVteyCjdDCxJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhQCCqcoOg[o9tdG:5ZXSgZpkhUDKRMjDh[IRqfGmxbjDmc5IhOiCqcoOgZpkhe3CnY4Tyc5Bpd3SxbXX0dpk> NVLOU3poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 M3rST2NiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl? MortNUB2VQ>? MofHPEBpenN? NWi5UpplS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IHnuJJJifCCKOXOyJINmdGy|IHHzd4V{e2WmIHHzJIFvfGmxeHnkZY51KGGldHn2bZR6KGK7IH3lZZN2emmwZzDpcoNz\WG|ZTDpckBUV0RiYXP0bZZqfHliYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDhiaILzJIZwdGyxd3XkJIJ6KEh{T{KgZYRlcXSrb36g[o9zKDJiaILzJIJ6KHOyZXP0do9xcG:2b33leJJ6 M3n0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 MXnDZZJlcW:ycn;0[YN1cX[nIHHzd4F6 NYPrW2JrOSC3TR?= NWf2PJFPQCCqcoO= M{nPPGNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCrbjDyZZQhUDmlMjDj[YxteyCjc4Pld5Nm\CCjczDhcpRqd3irZHHueEBi[3Srdnn0fUBjgSCvZXHzeZJqdmdiaX7jdoVie2ViaX6gZ4F1[Wyjc3WgZYN1cX[rdImgZZQhOSC3TTDwdoVqdmO3YnH0[YQh\m:{IEigbJJ{KG[xbHzve4VlKGK7IFiyU|Ih[WSmaYTpc44h\m:{IEKgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHK7 NUe1WoNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 NXjO[|J1S2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= MX2xJJVO MUm4JIhzew>? NGDicVFE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NibXXkbYF1\WRiaX7mcIFudWG2aX;uJIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHRPTi2jbIDoZUBqdiC|dYDldo5ifGGwdDDheEAyKHWPIIDy[Ylv[3WkYYTl[EBnd3JiODDodpMh\m:ubH;3[YQh[nliSELPNkBi\GSrdHnvckBnd3JiMjDodpMh[nliRVzJV2E> M2HPSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 NVXT[FJUS2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= M3XQfVEhfU1? MUO4JIhzew>? MUHDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC|dILld5MhdWWmaXH0[YQhcW6obHHtcYF1cW:wIHnuJJJifCCKOXOyJINmdGy|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIFnMMVFj\XSjIHnuJJN2eGW{bnH0ZY51KGG2IEGgeW0heHKnaX7jeYJifGWmIH\vdkA5KGi{czDmc4xtd3enZDDifUBJOk9{IHHk[Il1cW:wIH\vdkAzKGi{czDifUBGVEmVQR?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 NIf5[XRE[XKmaX;wdo91\WO2aY\lJIF{e2G7 NYPhXJdZOSC3TR?= MkDKPEBpenN? MX\DZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC|dILld5MhcW5icnH0JGg6[zJiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJG1FSSCuZY\lcJMh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK|IHnuJJBz\XOnbnPlJI9nKGynb371dolv\SCkeTDzdIVkfHKxcHjveI9u\XS{eR?= MmjJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 MUHDZZJlcW:ycn;0[YN1cX[nIHHzd4F6 NXO3O|BNOSC3TR?= MVK4JIhzew>? MlzlR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KGmwIILheEBJQWN{IHPlcIx{KGG|c3Xzd4VlKGG|IHHueIlwgGmmYX70JIFkfGm4aYT5JIJ6KG2nYYP1dolv\yCrbnPy[YF{\SCrbjDTU2Qh[WO2aY\peJkh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK|IHnuJJBz\XOnbnPlJI9nKGynb371dolv\SCkeTDzdIVk MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 MorJR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? MUmxJJVO NULJNGpyQCCqcoO= NVTmS|lnS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IH3l[IlifGWmIHnu[oxidW2jdHnvckBqdiC{YYSgTFlkOiClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBKVC14IHnuJJN2eGW{bnH0ZY51KGG2IEGgeW0heHKnaX7jeYJifGWmIH\vdkA5KGi{czDmc4xtd3enZDDifUBJOk9{IHHk[Il1cW:wIH\vdkAzKGi{czDpckBxemW|ZX7j[UBw\iCuZX;ueZJqdmViYomgSWxKW0F? NIDUTJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W3OVQ4OSd-Mke1O|U1PzF:L3G+
H9c2 M17FV2NiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl? MoDENUB2VQ>? M4DYW|ghcHK| M17NeWNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCvZXTpZZRm\CCrbn\sZY1u[XSrb36gbY4hemG2IFi5Z|Ih[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gTWwuOWKndHGgbY4he3WyZYLuZZRidnRiYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDhiaILzJIZwdGyxd3XkJIJ6KEh{T{KgZYRlcXSrb36g[o9zKDJiaILzJIlvKHC{ZYPlcoNmKG:oIHzlc452emmwZTDifUBGVA>? NFrEemY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W3OVQ4OSd-Mke1O|U1PzF:L3G+
H9c2 NIizOlBE[XKmaX;wdo91\WO2aY\lJIF{e2G7 MXmxJJVO MoXiPEBpenN? NVPDVHRqS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDjfZRwfG:6aXPpeJkhcW5icnH0JGg6[zJiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDhiaILzJIZwdGyxd3XkJIJ6KEh{T{KgZYRlcXSrb36g[o9zKDJiaILzJIJ6KE2WVDDhd5NigQ>? M4Xn[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
RAW264.7 NV3JUVZOSW62aXnu[oxidW2jdH;yfUBie3OjeR?= NYjkeYlqSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIHL5JI1m[XO3cnnu[{BvcXS{aYTlJIFk[3WvdXzheIlwdiCkeTDHdolme3NibXX0bI9lNCCLQ{WwQVQ{NjMQvF2= M4j5VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NU[xOVg3Lz5{OEW2NVU5PjxxYU6=
stem cells NV7Bd|kxTnWwY4Tpc44h[XO|YYm= NXTYcmZGOTByIIXN M3XVRlUh\GG7cx?= M{DOb2lv\HWldHnvckBw\iCjZHnwc4dmdmW|aYOgbY4hcHWvYX6gZo9v\SCvYYLyc5cu\GW{aY\l[EBu\XOnbnPofY1idCC|dHXtJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGGmaYDvcoVkfGmwIIDyc4R2[3Srb36gZZQhOTByIIXNJI1m[XO3cnXkJI9vKGSjeTC1JIlvKHC{ZYPlcoNmKG:oIFnEXEBjgSCHTFnTRS=> NXnw[4J[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzPVg1PDNpPkK5N|k5PDR|PD;hQi=>
DAOY NW\CXWp5eUiWUzDhd5NigQ>? M124W5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| MnG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 M3vRO5FJXFNiYYPzZZk> MoiwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN? NFHp[2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 MYLxTHRUKGG|c3H5 MXrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NVLiT5BGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
peritoneal cells NFWwTIlHfW6ldHnvckBie3OjeR?= MkPrOUBpenN? M2fVOWlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgVGdGOiCycn;keYN1cW:wIHnuJGM2P0KONjDtc5V{\SCyZYLpeI9v\WGuIHPlcIx{KG2nYYP1doVlKGG2IEWgbJJ{KHSrbXWgbY51\XK4YXygZpkhTUyLU1GsJGlEPTB;ND6wPO69VQ>? NE[wTFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE4Oid-M{CwNFYyPzJ:L3G+
HCT8 MmrLRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M{fDclczKGi{cx?= NWPldYhHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kBkcW6wYX3hcIRmcHmmZTDifUBOXFRiYYPzZZktKEmFNUC9NVUvPs7:TR?= MnG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{e0PVQoRjNyMEO3OFk1RC:jPh?=
RPMI8226 NYD6WXdPS2WubDDjfYNt\SCjc4PhfS=> M3HtZ|EvPyC3TR?= NYnSSlhKPDhiaILz M1zURmNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHJRVUl6MkK2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNE9IOSCyaHHz[UBifCBzLkegeW0hcW5icILld4Vv[2Vib3[gZo9zfGW8b33pZkBi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZT;SUoF{\SC|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{aXOgcYV1cG:mIILlcIF1cX[nIITvJIJwenSnen;tbYI> MkiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3OUCyOVgoRjNyNUmwNlU5RC:jPh?=
RPMI8226 NUPQRW93S2WubDDjfYNt\SCjc4PhfS=> MoTGNU44KHWP M1PhdlQ5KGi{cx?= M1vrXWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHJRVUl6MkK2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDTJJBp[XOnIHH0JFEvPyC3TTDpckBxemW|ZX7j[UBw\iCkb4L0[ZpwdWmkIHHmeIVzKDR6IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmN1KQYYPlJJN1[WmwaX7nJIJie2WmIH\sc5ch[3m2b33leJJq[yCvZYToc4QhemWuYYTpeoUhfG9iYn;yeIV7d22rYh?= MoLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3OUCyOVgoRjNyNUmwNlU5RC:jPh?=
RPMI8226 MVrD[YxtKGO7Y3zlJIF{e2G7 MoezNU44KHWP MVq0PEBpenN? NInteZVE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBTWE2LOEKyOkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2ViYYSgNU44KHWPIHnuJJBz\XOnbnPlJI9nKGKxcoTlfo9ucWJiYX\0[ZIhPDhiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUwWk6jc3Wgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dolkKG2ndHjv[EBz\WyjdHn2[UB1dyCkb4L0[ZpwdWmk M{nQ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUmwNlU5Lz5|MEW5NFI2QDxxYU6=
HaCaT MVTBcpRqeHm{ZYTpZ{Bie3OjeR?= MkC0NVAxKHWP NGjRSlQzKGi{cx?= NH:3Om9CdnSrcIny[ZRq[yCjY4Tpeol1gSCrbjDoeY1idiCKYVPhWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGTOSoFteGijLXnu[JVk\WRiUFfFNkBxem:mdXP0bY9vKGG2IEGwNEB2VSCycnWtbY5kfWKjdHXkJIZweiB{IHjyd{Bj\W[xcnWgWG5H[WyyaHGgd5RqdXWuYYTpc44h\m:{IEK0JIhzeyCkeTDFUGlUSQ>? NHHqWYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUO5N|EzPSd-M{GzPVMyOjV:L3G+
OVCAR5 NIfidZlHfW6ldHnvckBie3OjeR?= NWL0OmtVOzByIIXNJJRwKDFibV2= MmXKO|IhcHK| Mo\QTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBQXkODUkWgZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCkeTDt[YF{fXKrbnegdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIF1KDNyMDD1UUB1dyBzIH3NJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IGPSRkBie3OjeR?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
CCRF-CEM MXLGeY5kfGmxbjDhd5NigQ>? MnXaN{42KG2P MYm0PEBpenN? M3LWXGlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hS0OURj3DSW0h[2WubIOgZZN{\XO|ZXSgZZMheG:2ZX70bYF1cW:wIH;mJG5CVVCWIHnubIljcXSxcjDGT|g3Pi2rbnT1Z4VlKGGyb4D0c5NqeyCkeTDt[YF{fXKrbnegdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIF1KDNwNTDtUUBxemW{LXnuZ5Vj[XSnZDD3bZRpKEmFNUCgcIV3\Wxib3[gSms5PjZiZn;yJFQ5KGi{czDmc4xtd3enZDDifUBkd22yb4Xu[EBi\GSrdHnvckBidmRiZoXyeIhmeg>? M1fndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
Jurkat M2j0UmZ2dmO2aX;uJIF{e2G7 MXuzMlUhdU1? M1\5VFQ5KGi{cx?= M3fifWlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hUnW{a3H0JINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiRlu4OlYucW6mdXPl[EBieG:ydH;zbZMh[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA{NjVibV2gdJJmei2rbnP1ZoF1\WRid3n0bEBKSzVyIHzleoVtKG:oIF\LPFY3KG[xcjC0PEBpenNiZn;scI94\WRiYomgZ49ueG:3bnSgZYRlcXSrb36gZY5lKG[3coTo[ZIhcQ>? Ml3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlUwLz6FaFXNRmw9N2F-
ML2 NVfFOXN1TnWwY4Tpc44h[XO|YYm= MlzqN{42KG2P NIHHOJg1QCCqcoO= NXTtSmlGUW6qaXLpeIlwdiCxZjDORXBTXCCrbjDoeY1idiCPTEKgZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIFxd3C2b4Ppd{BjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFMvPSCvTTDwdoVzNWmwY4XiZZRm\CC5aYToJGlEPTBibHX2[Ywhd2ZiRlu4OlYh\m:{IES4JIhzeyCob3zsc5dm\CCkeTDjc41xd3WwZDDh[IRqfGmxbjDhcoQh\nW{dHjldkBqdmO3 NUnHTFgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
NOMO NVPt[lJYTnWwY4Tpc44h[XO|YYm= M{HhO|MvPSCvTR?= Mm\YOFghcHK| MWDJcohq[mm2aX;uJI9nKE6DUGLUJIlvKGi3bXHuJG5QVU9iY3XscJMh[XO|ZYPz[YQh[XNicH;0[Y51cWG2aX;uJI9nKE6DTWDUJIlvcGmkaYTvdkBHUzh4Nj3pcoR2[2WmIHHwc5B1d3OrczDifUBu\WG|dYLpcochemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEOuOUBuVSCycnXyMYlv[3WkYYTl[EB4cXSqIFnDOVAhdGW4ZXygc4YhTkt6Nk[g[o9zKDR6IHjyd{Bnd2yub4fl[EBjgSClb33wc5Vv\CCjZHTpeIlwdiCjbnSg[pVzfGincjDpcoM> NY\1Um9pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
NB4 M1q5cmZ2dmO2aX;uJIF{e2G7 MV:zMlUhdU1? NYPPSnprPDhiaILz MUnJcohq[mm2aX;uJI9nKE6DUGLUJIlvKGi3bXHuJG5DPCClZXzsd{Bie3Onc4Pl[EBieyCyb4TlcpRq[XSrb36gc4YhVkGPUGSgbY5pcWKrdH;yJGZMQDZ4LXnu[JVk\WRiYYDvdJRwe2m|IHL5JI1m[XO3cnnu[{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[XRiMz61JI1OKHC{ZYKtbY5kfWKjdHXkJJdqfGhiSVO1NEBt\X[nbDDv[kBHUzh4NjDmc5IhPDhiaILzJIZwdGyxd3XkJIJ6KGOxbYDveY5lKGGmZHn0bY9vKGGwZDDmeZJ1cGW{IHnuZ5U> NH23RYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
NAMALWA MWnGeY5kfGmxbjDhd5NigQ>? M33XV|MvPSCvTR?= MUG0PEBpenN? MlfKTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBPSU2DTGfBJINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiRlu4OlYucW6mdXPl[EBieG:ydH;zbZMh[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA{NjVibV2gdJJmei2rbnP1ZoF1\WRid3n0bEBKSzVyIHzleoVtKG:oIF\LPFY3KG[xcjC0PEBpenNiZn;scI94\WRiYomgZ49ueG:3bnSgZYRlcXSrb36gZY5lKG[3coTo[ZI> NEjzXo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
Daudi M1XITmZ2dmO2aX;uJIF{e2G7 NWfKVI5ZOy53IH3N Ml[5OFghcHK| Mn35TY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBF[XWmaTDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv NIXvPIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
Raji MnOwSpVv[3Srb36gZZN{[Xl? MoXLN{42KG2P MVW0PEBpenN? NHrDbolKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKFKjanmgZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIFxd3C2b4Ppd{BjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFMvPSCvTTDwdoVzNWmwY4XiZZRm\CC5aYToJGlEPTBibHX2[Ywhd2ZiRlu4OlYh\m:{IES4JIhzeyCob3zsc5dm\CCkeTDjc41xd3WwZDDh[IRqfGmxbjDhcoQh\nW{dHjldkBqdmN? NHW5U|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
ARH77 NYnQUmdPTnWwY4Tpc44h[XO|YYm= NH;rNYM{NjVibV2= M4j4PVQ5KGi{cx?= MXPJcohq[mm2aX;uJI9nKE6DUGLUJIlvKGi3bXHuJGFTUDd5IHPlcIx{KGG|c3Xzd4VlKGG|IIDveIVvfGmjdHnvckBw\iCQQV3QWEBqdmirYnn0c5IhTkt6Nk[tbY5lfWOnZDDhdI9xfG:|aYOgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCzMlUhdU1icILldk1qdmO3YnH0[YQhf2m2aDDJR|UxKGyndnXsJI9nKE[NOE[2JIZweiB2ODDodpMh\m:ubH;3[YQh[nliY3;tdI92dmRiYXTkbZRqd25iYX7kJIZ2enSqZYKgbY4> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
RPMI8226 NY\vVIJwTnWwY4Tpc44h[XO|YYm= M{Hw[FMvPSCvTR?= MV:0PEBpenN? M1q1dWlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hWlCPSUiyNlYh[2WubIOgZZN{\XO|ZXSgZZMheG:2ZX70bYF1cW:wIH;mJG5CVVCWIHnubIljcXSxcjDGT|g3Pi2rbnT1Z4VlKGGyb4D0c5NqeyCkeTDt[YF{fXKrbnegdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIF1KDNwNTDtUUBxemW{LXnuZ5Vj[XSnZDD3bZRpKEmFNUCgcIV3\Wxib3[gSms5PjZiZn;yJFQ5KGi{czDmc4xtd3enZDDifUBkd22yb4Xu[EBi\GSrdHnvckBidmRiZoXyeIhmeg>? NYrQ[mVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
U266 M4Dmd2Z2dmO2aX;uJIF{e2G7 Mlq0N{42KG2P MkC1OFghcHK| MonKTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBWOjZ4IHPlcIx{KGG|c3Xzd4VlKGG|IIDveIVvfGmjdHnvckBw\iCQQV3QWEBqdmirYnn0c5IhTkt6Nk[tbY5lfWOnZDDhdI9xfG:|aYOgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCzMlUhdU1icILldk1qdmO3YnH0[YQhf2m2aDDJR|UxKGyndnXsJI9nKE[NOE[2JIZweiB2ODDodpMh\m:ubH;3[YQh[nliY3;tdI92dmRiYXTkbZRqd25iYX7kJIZ2enSqZYKgbY5k M3q1XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
NAMALWA MVvGeY5kfGmxbjDhd5NigQ>? MVSzOUBu\y:tZx?= M3S3e|Q2KGSjeYO= NIHYbXNRd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IEGwJI1oN2upLDDpdEBjcWRiRlu4OlYucW6mdXPl[EBidnSrdIXtc5Ih[WO2aY\peJkhcW5iaIXtZY4hVkGPQVzXRUBk\WyuczD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKG2xdYPlJJN2en[rdnHsJIF1KDN3IH3nM4toNCCrcDDibYQhfXBidH:gOFUh\GG7cx?= NV7KTXJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
SHH / SMO / GLI1 / Bcl-2 / Foxm1 ; 

PubMed: 28446712     


Western blot analysis showed SHH, SMO, GLI1, Bcl-2 and Foxm1 proteins expression in U87 and T98G cells treated with indicated concentrations of aspirin for 24 h. GAPDH was used as an internal control. 

PubMed: 23741443     


Western blotting revealed that aspirin down-regulated COX1 and COX2 expression in HCC cell lines.

p-AMPKα / AMPKα / p-ACC / ACC; 

PubMed: 26918349     


Western blot analysis of the effects of aspirin on AMPK and ACC phosphorylation.

p-AKT / AKT / p-ERK / ERK ; 

PubMed: 26918349     


Western blot analysis of the effects of aspirin on Akt and ERK1/2 phosphorylation.

MCL-1; 

PubMed: 26918349     


Western blot analysis of the effects of aspirin on MCL-1 expression.

28446712 23741443 26918349
Growth inhibition assay
Cell viability; 

PubMed: 30221683     


The CCK-8 assay results are presented as bar graphs for the antiproliferative effects of aspirin on RA-FLS. (A-C) RA-FLS were treated with (0, DMSO, 1, 2, 5 and 10 mM) aspirin for 12, 24 and 48 h. At each time interval, cell viability was determined by CCK-8 analysis. Data are presented as the means ± SD (error bars) from three independent experiments. Aspirin inhibited the growth of RA-FLS in a dose-dependent manner. (D) Cell proliferation decreased at 12, 24 and 48 h. Data are presented as the means ± SD (error bars) from three independent experiments. *P<0.05, **P<0.01, ***P<0.001 vs. DMSO group. CCK-8: Cell-Counting Kit-8; RA-FLS, rheumatoid arthritis-fibroblast-like synoviocytes; DMSO, dimethyl sulfoxide; SD, standard deviation.

Cell proliferation ; 

PubMed: 28446712     


U87 and T98G cells were treated with indicated concentrations of aspirin and harvested after 24, 48 and 72 h. Cell proliferation was analyzed by CCK-8 assay. 

30221683 28446712

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 36 mg/mL (199.82 mM)
Water Insoluble
Ethanol ''36 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+PBS
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 180.16
化学式

C9H8O4

CAS号 50-78-2
储存条件 粉状
溶于溶剂
别名 Acetylsalicylic acid, ASA

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04563546 Not yet recruiting Other: Quality Improvement Acute Coronary Syndrome Duke University January 1 2023 Not Applicable
NCT05031455 Not yet recruiting Biological: Dupilumab|Drug: Placebo Aspirin-exacerbated Respiratory Disease Scripps Clinic|University of California San Diego|Regeneron Pharmaceuticals January 1 2022 Phase 2
NCT04308551 Not yet recruiting Drug: Indobufen|Drug: Aspirin Stable Coronary Heart Disease Henan Institute of Cardiovascular Epidemiology December 30 2021 Not Applicable
NCT04974892 Not yet recruiting Diagnostic Test: Blood test Preeclampsia|Neutrophil|Immunology|Pregnancy Queen Mary University of London September 1 2021 --
NCT04811625 Not yet recruiting Drug: PL-ASA Healthy Volunteers PLx Pharma May 2021 Phase 4
NCT04851964 Recruiting Biological: Experimental: Tezepelumab|Other: Placebo Chronic Rhinosinusitis With Nasal Polyps AstraZeneca|Amgen April 22 2021 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

COX Signaling Pathway Map

相关COX产品

Tags: 购买Aspirin (NSC 27223) | Aspirin (NSC 27223)供应商 | 采购Aspirin (NSC 27223) | Aspirin (NSC 27223)价格 | Aspirin (NSC 27223)生产 | 订购Aspirin (NSC 27223) | Aspirin (NSC 27223)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID